Your browser doesn't support javascript.
loading
Impact of cachexia on outcomes in aggressive lymphomas.
Karmali, Reem; Alrifai, Taha; Fughhi, Ibtihaj A M; Ng, Ronald; Chukkapalli, Vineela; Shah, Palmi; Basu, Sanjib; Nathan, Sunita; Szymanski-Grant, Kelly; Gordon, Leo I; Venugopal, Parameswaran; Penedo, Frank J; Borgia, Jeffrey A.
Afiliação
  • Karmali R; Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, USA. reem.karmali@northwestern.edu.
  • Alrifai T; Rush University Medical Center, Chicago, IL, USA.
  • Fughhi IAM; Rush University Medical Center, Chicago, IL, USA.
  • Ng R; University of Illinois, Chicago, IL, USA.
  • Chukkapalli V; Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, USA.
  • Shah P; Department of Radiology, Rush University Medical Center, Chicago, IL, USA.
  • Basu S; Rush University Medical Center, Chicago, IL, USA.
  • Nathan S; Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, USA.
  • Szymanski-Grant K; Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, USA.
  • Gordon LI; Division of Hematology, Oncology, Northwestern University, Chicago, IL, USA.
  • Venugopal P; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
  • Penedo FJ; Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, USA.
  • Borgia JA; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Ann Hematol ; 96(6): 951-956, 2017 Jun.
Article em En | MEDLINE | ID: mdl-28417157
ABSTRACT
Cancer cachexia is defined as a state of involuntary weight loss, attributed to altered body composition with muscle mass loss and/or loss of adiposity. Identifying the association between cancer cachexia and outcomes may pave the way for novel agents that target the cancer cachexia process. Clinical parameters for measurement of cancer cachexia are needed. We conducted a single-institution retrospective analysis that included 86 NHL patients with the aim of identifying an association between cancer cachexia and outcomes in aggressive lymphomas using the cachexia index (CXI) suggested by Jafri et al. (Clin Med Insights Oncol 987-93, 15). Impact of cachexia factors on progression-free survival (PFS) and overall survival (OS) were assessed using log-rank test and Cox proportional hazards regression. Patients were dichotomized around the median CXI into "non-cachectic" (CXI ≥49.8, n = 41) and "cachectic" (CXI <49.8, n = 40) groups. Cachectic patients had significantly worse PFS (HR 2.18, p = 0.044) and OS (HR = 4.05, p = 0.004) than non-cachectic patients. Cachexia as defined by the CXI is prognostic in aggressive lymphomas and implies that novel therapeutic strategies directed at reversing cachexia may improve survival in this population.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Caquexia / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Caquexia / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos